Tom Henley, Ph.D. is an Associate Director of R&D at Horizon Discovery PLC. His research is focused on improving the genome editing technologies that enable the generation of mutant cell lines, primarily the recombinant adeno associated virus (rAAV) and CRISPR nuclease platforms. He joined Horizon Discovery in 2010, leading a team dedicated to the engineering of complex mutations in diverse cell backgrounds and soon concentrated his attention on ways to increase the efficiency of introducing precise genetic changes into mammalian cells. Prior to joining Horizon, Dr Henley was a postdoctoral researcher at the Babraham Institute in Cambridge where he used genome engineering to study the role of microRNAs in lymphocyte development. Dr Henley holds a B.Sc. in Molecular Genetics from King’s College London and received his Ph.D. from the University of Cambridge where he studied the development of the immune system through the generation and application of transgenic animal models.